Binding parameters and microbiological activity of macrolides, lincosamides and streptogramins against Staphylococcus aureus. 1987

M P Fournet, and J Barre, and R Zini, and L Deforges, and J Duval, and J P Tillement

Parameters of erythromycin binding to Staphylococcus aureus were measured in-vitro using an equilibrium method with [3H]erythromycin. The dissociation constant of the complex, erythromycin-S. aureus sensitive strain, was KD = 0.11 microM. The maximal binding, representing the density of binding sites was 14,847 molecules/cell. No binding was detectable on the constitutive resistant strain. Macrolides, streptogramins and lincosamides displaced bound [3H]erythromycin by a competitive process indicating that these compounds share common binding sites on the bacteria, i.e. 50 S ribosomal subunits. A good correlation (r = 0.99) was demonstrated between the corresponding inhibition constants (Ki) and the minimal inhibitory concentration. It is proposed that knowledge of the binding parameters provides a good indication of bacterial susceptibility and may serve as a useful adjunct in developing new compounds.

UI MeSH Term Description Entries
D004917 Erythromycin A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins. Erycette,Erymax,Erythromycin A,Erythromycin C,Erythromycin Lactate,Erythromycin Phosphate,Ilotycin,T-Stat,Lactate, Erythromycin,Phosphate, Erythromycin,T Stat,TStat
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D013211 Staphylococcus aureus Potentially pathogenic bacteria found in nasal membranes, skin, hair follicles, and perineum of warm-blooded animals. They may cause a wide range of infections and intoxications.
D014316 Tritium The radioactive isotope of hydrogen also known as hydrogen-3. It contains two NEUTRONS and one PROTON in its nucleus and decays to produce low energy BETA PARTICLES. Hydrogen-3,Hydrogen 3
D014769 Virginiamycin A cyclic polypeptide antibiotic complex from Streptomyces virginiae, S. loidensis, S. mitakaensis, S. pristina-spiralis, S. ostreogriseus, and others. It consists of 2 major components, VIRGINIAMYCIN FACTOR M1 and virginiamycin Factor S1. It is used to treat infections with gram-positive organisms and as a growth promoter in cattle, swine, and poultry. Staphylomycin,Antibiotic 899,Eskalin,Founderguard,Stajac,Virgimycine
D055231 Lincosamides A family of LINCOMYCIN-related glycosides that contain a pyrrolidine ring linked via an amide-bond to a pyranose moiety. Individual members of this family are defined by the arrangement of specific constituent groups on the lyncomycin molecule. Many lincosamides are ANTIBIOTICS produced by a variety STREPTOMYCES species.
D018942 Macrolides A group of often glycosylated macrocyclic compounds formed by chain extension of multiple PROPIONATES cyclized into a large (typically 12, 14, or 16)-membered lactone. Macrolides belong to the POLYKETIDES class of natural products, and many members exhibit ANTIBIOTIC properties. Macrolide

Related Publications

M P Fournet, and J Barre, and R Zini, and L Deforges, and J Duval, and J P Tillement
February 1987, Journal of pharmaceutical sciences,
M P Fournet, and J Barre, and R Zini, and L Deforges, and J Duval, and J P Tillement
July 1985, The Journal of antimicrobial chemotherapy,
M P Fournet, and J Barre, and R Zini, and L Deforges, and J Duval, and J P Tillement
January 2007, Medycyna doswiadczalna i mikrobiologia,
M P Fournet, and J Barre, and R Zini, and L Deforges, and J Duval, and J P Tillement
March 2007, The Journal of the Oklahoma State Medical Association,
M P Fournet, and J Barre, and R Zini, and L Deforges, and J Duval, and J P Tillement
January 2006, Microbial drug resistance (Larchmont, N.Y.),
M P Fournet, and J Barre, and R Zini, and L Deforges, and J Duval, and J P Tillement
February 2011, International journal of antimicrobial agents,
M P Fournet, and J Barre, and R Zini, and L Deforges, and J Duval, and J P Tillement
January 2001, Microbial drug resistance (Larchmont, N.Y.),
M P Fournet, and J Barre, and R Zini, and L Deforges, and J Duval, and J P Tillement
September 2019, Acta microbiologica et immunologica Hungarica,
M P Fournet, and J Barre, and R Zini, and L Deforges, and J Duval, and J P Tillement
July 1985, The Journal of antimicrobial chemotherapy,
M P Fournet, and J Barre, and R Zini, and L Deforges, and J Duval, and J P Tillement
July 1985, The Journal of antimicrobial chemotherapy,
Copied contents to your clipboard!